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Open access under CC BYMicroglia mediate multiple facets of neuroinﬂammation, including cytotoxicity, repair, regeneration, and
immunosuppression due to their ability to acquire diverse activation states, or phenotypes. Modulation
of microglial phenotype is an appealing neurotherapeutic strategy but a comprehensive study of classical
and more novel microglial phenotypic markers in vitro is lacking. The aim of this study was to outline the
temporal expression of a battery of phenotype markers from polarised microglia to generate an in vitro
tool for screening the immunomodulatory potential of novel compounds. We characterised expression
of thirty-one macrophage/microglial phenotype markers in primary microglia over time (4, 12, 36, and
72 h), using RT-qPCR or multiplex protein assay. Firstly, we selected Interleukin-4 (IL-4) and lipopolysac-
charide (LPS) as the strongest M1–M2 polarising stimuli, from six stimuli tested. At each time point,
markers useful to identify that microglia were M1 included iNOS, Cox-2 and IL-6 and a loss of M2a mark-
ers. Markers useful for quantifying M2b-immunomodulatory microglia included, increased IL-1RA and
SOCS3 and for M2a-repair and regeneration, included increased arginase-1, and a loss of the M1 and
M2b markers were discriminatory. Additional markers were regulated at fewer time points, but are still
likely important to monitor when assessing the immunomodulatory potential of novel therapies. Further,
to facilitate identiﬁcation of how novel immunomodulatory treatments alter the functional affects of
microglia, we characterised how the soluble products from polarised microglia affected the type and rate
of neuronal death; M1/2b induced increasing and M2a-induced decreasing neuronal loss. We also
assessed any effects of prior activation state, to provide a way to identify how a novel compound may
alter phenotype depending on the stage of injury/insult progression. We identiﬁed generally that a prior
M1/2b reduced the ability of microglia to switch to M2a. Altogether, we have characterised a proﬁle of
phenotype markers and a mechanism of assessing functional outcome that we can use as a reference
guide for ﬁrst-line screening of novel immunomodulatory therapies in vitro in the search for viable
neuroprotectants.
 2013 Elsevier Inc. Open access under CC BY license.pital Robert Debré, 48 Blvd.
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 license.1. Introduction
In response to insult or injury microglia and macrophages are
capable of acquiring diverse and complex phenotypes, allowing
them to participate in the cytotoxic response, immune regulation,
and injury resolution. Nomenclature of these phenotypes varies
across the literature (Kreider et al., 2007; Martinez et al., 2008)
but can be characterised into four main states, classically activated
M1with cytotoxic properties; M2a with an alternate activation and
involved in repair and regeneration; M2b with an immunoregula-
tory phenotype; or M2c with an acquired-deactivating phenotype.
V. Chhor et al. / Brain, Behavior, and Immunity 32 (2013) 70–85 71The concept of phenotype, including nomenclature, and its impor-
tance in our understanding of injury processes and drug design
and has been extensively reviewed elsewhere (Mosser and
Edwards, 2008; Martinez et al., 2009; Ransohoff and Perry, 2009;
Perry et al., 2010; Weinstein et al., 2010).
Microglia are self-renewing and long-lived resident macro-
phage-like cells of the brain (Giulian and Baker, 1986; Glenn
et al., 1992; Kettenmann et al., 2011). In addition to important
roles in inﬂammation, microglia are also critical in developmental
processes such as synaptogenesis, and are imperative for the main-
tenance of neural homeostasis (see, Tremblay et al., 2011; Ekdahl,
2012). Importantly, microglial phenotypes reﬂect expression of cell
surface receptors and release of soluble factors with recognised
functions. Over time following injury and over time in vitro in re-
sponse to stimuli, expression of the markers used to characterise
these states changes (Perego et al., 2011; Hu et al., 2012). Beneﬁcial
for our ability to study these populations, phenotypes have known
prototypical inducers; Toll-like-receptor-4 agonist lipopolysaccha-
ride (LPS), IFNc and TNFa for M1; IL-4 and IL-13 for M2a; immune
complexes and toll-like-receptor agonists, and IL-1R ligands for
M2b; and IL-10, TGF-b and glucocorticoids for M2c. However, a
great deal of the studies outlining these inducers were performed
in peritoneal or blood derived macrophages, and microglia are
known to differ in their responsiveness to stimuli (Schmid et al.,
2009).
Inﬂammatory processes, including activation of microglia, are
initiated in the adult and perinatal brain after most (if not all) types
of insults and injury (see, Degos et al., 2010; Perry et al., 2010; Bilbo
et al., 2012; Fleiss and Gressens, 2012; Hagberg et al., 2012). The
importance of microglia in protecting the brain is illustrated by
the observation that complete blockade of microglial activity exac-
erbates brain damage in adult and neonatal hypoxic ischemic injury
models (Lalancette-Hebert et al., 2007; Faustino et al., 2011). Also, it
is possible for neurotherapeutics to be effective in the neonatal
brain without reducing microglial number, also suggesting that
modulation rather than suppression may be important (Doverhag
et al., 2010; Fleiss et al., 2012). In fact, cell therapy with microglia
has been shown to reduce injury in a model of adult hypoxic/ische-
mic injury (Imai et al., 2007). All together these observations sup-
port the need for screening tools to identify neurotherapeutics
that support a repair and regenerative microglial phenotype.
Cultured primary microglia are a useful ﬁrst line research tool
with which to screen the immunomodulatory potential of novel
therapeutics. Primary microglial cultures derived from early post-
natal rodents have cell surface receptor expression and functional
characteristics similar to that seen in microglia in vivo (Giulian and
Baker, 1986; Henn et al., 2009). However, despite the enormous
wealth of information regarding macrophage/microglial pheno-
type, to the best of our knowledge there is no comprehensive time
and stimulus dependent data on the phenotype of primary microg-
lia. In addition, a great deal of our understanding of phenotype is
derived from studies of macrophages. However, the responses of
resident microglia differ from that of the circulating macrophages
that inﬁltrate the brain during insult/injury (Lalancette-Hebert
et al., 2007; Schmid et al., 2009), suggested to relate to differing
origin of these cell types (Saijo and Glass, 2011). As such, it is crit-
ical to understand the speciﬁc functions and responses of microg-
lia. Thus, the aim of this study was to characterise in primary
microglia the expression of a battery of classic (IL-6, iNOS etc.)
and more novel phenotype markers (SphK1/2, FIZZ1 etc.) in a time
and stimulus dependent manner and to create a functional output
with which to evaluate the neuronotoxic effects of phenotype. We
propose that this data set represents an in vitro model, useful as a
ﬁrst-line screening tool, to assess the immunomodulatory poten-
tial of novel neurotherapeutics in microglia of an M1 or M2
phenotype.2. Methods
2.1. Animals
Animals were handled according to institutional guidelines of
Institut National de la Santé et de la Recherche Scientiﬁque (In-
serm) France, or the Gothenburg University Sweden Animal Ethics
Committee and met the guidelines for the Care and use of labora-
tory animals (NIH, Bethesda, Maryland, USA). Experiments were
performed using OF1 strain mice from Charles River (L’Arbresle,
France).
2.2. Drugs
Lipopolysaccharide (LPS; Sigma, Lyon, France, L2880, lot
050M4014) was diluted in PBS to a stock concentration of
0.1 mg/mL. Cytokines were from R&D systems (Lille Cedex, France),
and diluted in PBS and 0.1% bovine serum albumin to create stock
solutions; 5 lg/mL for IL-1b, 1 lg/mL for tumour necrosis factor-a
(TNFa) and 2 lg/mL for IL-4; IL-10; and Interferon-c (IFNc).
2.3. Primary microglial culture
Primary mixed glial cell cultures were prepared from the corti-
ces of postnatal day (P) 0–1 OF1 mice, as previously described
(Thery et al., 1991). Pups of both sexes were included and on aver-
age an equal number of males and females were included in each
culture. After dissection of the cortices in 0.1 M PBS with 6% glu-
cose and 2% penicillin–streptomycin (PS; Gibco, Cergy Pontoise,
France) and removal of the meninges, the cortices were chopped
into small pieces and subsequently mechanically dissociated. The
suspension was diluted in pre-cooled low glucose Dulbecco’s mod-
iﬁed Eagle’s minimum essential medium (DMEM, 31885, Gibco)
supplemented with 10% foetal bovine serum (FBS, Gibco) and
0.01% PS. Microglia were isolated from primary mixed glial cul-
tures on day in vitro 14 (DIV14) using a reciprocating shaker
(20 min at room temperature) and repeated rinsing with their
medium using a 10 mL pipette. Media was subsequently removed,
microglia pelleted via centrifugation (300g  10 min) and follow-
ing resuspension maintained in DMEM supplemented with 10%
FBS at a concentration of 4  105 cells/mL in 6-well culture plates.
Culture purity was veriﬁed by immunostaining (n = 5) using cell-
type speciﬁc antibodies against tomato lectin (microglia), glial
ﬁbrillary acidic protein (GFAP; astrocytes) and neuronal nuclear
antigen (NeuN; neurons) and revealed a >99% purity of microglia.
Based on previous reports, the day after plating, microglia were
treated with PBS (vehicle; 10 ll/ml of culture media), LPS at 1 lg/
mL (Takeuchi et al., 2006; Kaindl et al., 2012), IL-1b at 50 ng/mL
(Street et al., 2003; Hjorth et al., 2010), IL-4 at 20 ng/mL (Butovsky
et al., 2006; Kigerl et al., 2009), IL-10 at 20 ng/mL (Strle et al.,
2002), TNFa at 10 ng/mL (Bernardino et al., 2005), or IFNc at
20 ng/mL (Butovsky et al., 2006; Kigerl et al., 2009). After various
exposure times (4, 12, 36, and 72 h) supernatant (conditioned
media) was collected and stored at 80 C until analysis of cyto-
kine/chemokine levels or for use in neuronal viability studies,
and cells were harvested and RNA extracted for gene expression
analysis. A schematic representation of the experimental timelines
is shown in Fig. 1.
2.4. Primary neuronal cultures
Cultured neurons were derived from the cerebral cortex of
embryonic (E) 14.5 mice as previously described (Fontaine et al.,
2008). After dissection of the cortices and removal of the meninges
the cortices were minced into small pieces, chemically dissociated
Fig. 1. Schematic representation of the experimental setups, including phenotyp-
ing, neuronal viability and phenotyping switching experiments.
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20 min. The reaction was stopped by addition of 0.001% horse ser-
um, and cortex pieces were subsequently mechanically dissoci-
ated. Cells were seeded in 8-well Ibitreat slide (Ibidi, Biovalley,
Marne-La-Vallée, France) pre-coated with 30 lg/mL poly-DL-
ornithine (PO, Sigma) at 12.5  104 cells per well to a ﬁnal volume
of 250 lL per well. Cells were cultured in Neurobasal Medium
(Gibco) supplemented with 2% B27 (Gibco), 1% glutamine 100
(Gibco) and 0.05% PS. One third of the culture medium was ex-
changed for fresh solution twice a week and arabinocytidine
hydrochloride (Ara C: 5 lM, Sigma, C1768) was added at DIV4.
At DIV6, one third of neuronal media was exchanged with con-
ditioned media from microglia exposed to LPS for 12 h or IL-4 for36 h, as described above. At 5, 8, and 14 h after exposure to condi-
tioned media neurons were stained with markers of cell death,
using the protocol described below.
2.5. RNA extraction and quantiﬁcation of gene expression by real-time
qPCR
Total RNA from primary microglial cell cultures was extracted
with the RNeasy mini kit according to the manufacturer’s instruc-
tions (Qiagen, Courtaboeuf, France). RNA quality and concentration
were assessed by spectrophotometry with the Nanodrop™ appara-
tus (Thermoscientiﬁc, Wilmington, DE, USA). Total RNA (1–2 lg)
was subjected to reverse transcription using the iScript™ cDNA
synthesis kit (Bio-Rad, Marnes-la-Coquette, France). RT-qPCR was
performed in duplicate for each sample using SYBR Green Super-
mix (Bio-Rad) for 40 cycles with a 2-step program (5 s of denatur-
ation at 96 C and 10 s of annealing at 60 C). Ampliﬁcation
speciﬁcity was assessed with a melting curve analysis. Primers
were designed using Primer3 software, and sequences and their
NCBI references are given in Supplementary Table 1. The relative
expression of genes of interest (GOI) were expressed relative to
expression of the reference gene, Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Analyses were performed with the Biorad
CFX manager 2.1 software.
2.6. Multiplex cytokine/chemokine assay
Microglia media harvested at different time-points following
treatment initiation was centrifuged brieﬂy to remove particulates
(300g for 10 min). Cytokine and chemokine levels in the microglial
supernatant were measured using a Bio-plex 200 with a 96-well
magnetic plate assay according to the manufacturers instructions
(Biorad laboratories, Marnes la Coquette, France). Cytokine and
chemokine measured included IL-1a, IL-1b, IL-2, IL-6, IL-10, IL-12
(p70), IL-13, G-CSF, GM-CSF, IFNc, TNFa, CXCL1 (KC), CCL2 (MCP-
1), and CCL5 (RANTES). All samples were run in duplicates and data
was analysed with the Bio-Plex Manager software.
2.7. Cell viability (mitochondrial activity) assay
Microglial viability was quantiﬁed using the colorimetric CellT-
iter 96 A Queous Non-Radioactive Cell Proliferation Assay (Pro-
mega, Madison, WI, USA) per manufacturer instructions. In this
assay, MTS a tetrazolium dye is bioreduced by the mitochondria
into a formazan product that is soluble in tissue culture medium.
In brief, 20 lL of the MTS solution was added to each well of a
96-well-plate containing 40  103 microglial cells 12 h following
treatment with PBS, LPS or IL-4 and the absorbance of formazan
was measured 1 h later at 490 nm using the Beckman Coulter Par-
adigm Detection Platform (Beckman, Fullerton, CA, USA).
2.8. Fluorescence immunohistochemistry for cell death markers in
neurons
Neurons were stained at various time points following exposure
to microglial conditioned media, to assess the type and percentage
of neuronal cell death. Loss of plasma membrane integrity was de-
tected through increased permeability to 7-Amino Actinomycin D
(7-AAD, 1 lg/mL; Molecular Probes, A1310). Externalisation of
phosphatidylserine (PI; Molecular Probes, A13201), a characteristic
of apoptosis, was detected with Alexa Fluor 594-conjugated-
Annexin V (1/60 dilution; Molecular Probes, A13201). Nuclear
morphology and total cell number was visualised using the DNA
binding dyes Hoechst 33342 (1 lg/mL; Sigma, B2261). Neurons
were cultured at 37 C for 30 min with 7-AAD, Annexin V and Hoe-
chst and following thorough washing with PBS, ﬂuorescence
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objective. 7-AAD was observed using 528–553 nm excitation/
590–650 nm emission ﬁlter, Annexin V at 465–495 nm excita-
tion/515–555 nm emission ﬁlter and Hoechst at 340–380 nm exci-
tation/435–485 nm emission ﬁlter. Images for analysis were
acquired with a Coolsnap HQ2 camera and staining assessed with
the Nikon NIS Elements and Image J software. Neurons were clas-
siﬁed into one of four populations; (i) cells negative for 7-AAD and
Annexin V (viable cells), (ii) cells positive only for Annexin V (early
apoptotic), (iii) cells positive to both Annexin V and 7-AAD (late
apoptotic or necrotic), and, (iv) cells positive only to 7-AAD (early
necrotic). Data for each marker was adjusted to the total number of
Hoechst positive cells per ﬁeld of view.
2.9. Fluorescence immunohistochemistry of microglia
To immunolabel microglia, cell medium was removed and cells
were ﬁxed with Histoﬁx (Histolab, Sweden, Gothenburg). Fixed
cells were treated with PBS-Triton X 100 (0.5%) for 20 min and pri-
mary antibodies applied overnight at 4 C. Antibodies used in-
cluded; Monoclonal Mouse anti-Arginase 1, 1:50, 610708, (BD
Biosciences, London, UK); Monoclonal Rat anti-CD86, 1:100,
550542, (BD Biosciences); Polyclonal Rabbit anti-iNOS, 1:50,
610332, (BD Biosciences); Polyclonal Goat anti-IL-1RA, 1:400, Sc-
8482, (Santa Cruz, CA, USA); Polyclonal Rabbit anti-Cox-2, 1:400,
Ab15191, (Abcam, Cambridge, UK), and; Polyclonal Rabbit anti-
Ki67, NCL-Ki67-P, 1:1000, (Novocastra, Newcastle Upon Tyne,
UK). After thorough washing the appropriate Alexa 488 or 594 con-
jugated ﬂuorescent secondary antibody (1:500, Invitrogen, Stock-
holm, Sweden) was applied for 1 h at room temperature.
Speciﬁcity of staining was checked by including no-primary and
no-secondary antibody controls during staining. Cells were covers-
lipped with Prolong Gold DAPI (Invitrogen) or Hoechst, and ana-
lysed using Zeiss Axio Imager.Z2 with the ZEN 2011 Blue software.
2.10. Statistics
Data are from three or more independent microglial or neuronal
cultures and are presented as mean ± SEM. Data were assessed for
normality. Gene and protein expression over time was analysed
with an ANOVA and a Bonferroni post-test. Neuronotoxicity was
analysed with a Kruskal–Wallis and a Dunns post-test. SwitchingTable 1
Markers assessed in this study whose expression in associated with speciﬁc phenotype
dependent (Adapted and compiled from, Mosser and Edwards, 2008, Colton, 2009, Ransoh
Proposed role in inﬂ
Inﬂammotoxic Pr
M1 classic phenotype (cytotoxic) TNFa IL
iNOS IL
IL
IF
CX
IL
IL
CC
M2a alternate phenotype (repair and regeneration)
M2b (c) Type II-deactivating phenotype (immunomodulatory)effects on phenotype was analysed via a Student’s t-test or
Mann–Whitney test. Signiﬁcance from the Student’s t-test, Mann
Whitney or the ANOVA post-test is shown on the graphs
(§p = 0.05; ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001). Statistics used for
each data set are indicated in the ﬁgure legends. Analyses were
performed with Graphpad 5.0 software (San Diego, CA, USA), and
p 6 0.05 was accepted as statistically signiﬁcant.
2.11. Nomenclature of microglial phenotype
We have adopted nomenclature consistent with the separate
works of Mantovani, Gordon, Colton, and Perry (Mantovani et al.,
2004; Colton, 2009; Martinez et al., 2009; Ransohoff and Perry,
2009); classically activated M1; M2a alternate activation repair/
regeneration; M2b immunoregulatory; and M2c acquired-deacti-
vating. However, due to a great deal of overlap between the pheno-
typic markers for M2b and M2c we have chosen to discuss M2c
only in the context of IL-10 dependent effects, but not ascribe par-
ticular markers to this phenotype.
3. Results
3.1. LPS and IL-4 induce robust M1/2b and M2a phenotypes
respectively
Our ﬁrst aim was to determine which stimuli from a selection of
those previously used to polarise microglia/macrophages would
most clearly polarise microglia in our culture conditions (i.e., to a
cytotoxic M1 vs. repair and deactivating M2 phenotype). We ex-
posed primary microglia to LPS, IL-1b, TNFa, IL-10, IL-4 or IFNc
for either 4 or 12 h and assessed gene expression of 17 phenotype
markers and protein levels of 7 phenotype markers, the proposed
functions of which are outlined in Table 1. Markers were character-
ised as M1, M2a or M2b based on previous reports (Mantovani
et al., 2004; Martinez et al., 2009; Ransohoff and Perry, 2009;
Colton andWilcock, 2010). Patterns of gene and protein expression
were similar at 4 and 12 h (Table 2; Supplementary Table 2).
Prototypical pro-inﬂammatory stimuli (LPS, IL-1b and TNFa),
increased gene expression of known cytotoxic M1 markers, Cox-2
and iNOS and as well as release of CXCL1/KC, TNFa, IL-6, and
IL-1b proteins (Table 2). Moreover, exposure to LPS, IL-1b, and
TNFa increased expression of immunomodulatory M2b markers,s and their generalised functions; functions are known to overlap and be context
off and Perry, 2009, Mantovani et al., 2009).
ammation
o-inﬂammatory Anti-inﬂammatory Repair Immunoregulatory
-1b
-6
-12
Nc
CL1 (KC)
-1a
-2
L5 (RANTES) Cox-2
IL-4 YM1 CD206 (MRC1)
IL-1RA (IL-1Rn) FIZZ1 Gal-3
CX3CR1 (fractalkine receptor) IGF-1 CCL2 (MCP-1)
Arg1 CCR2 (CD192)
TGF-b G-CSF
GM-CSF
IL-10
Cox-2
SphK1/2
SOCS3
IL-4Ra
Table 2
Expression (gene, G or protein, P) after 12 h stimulation of phenotype markers relative to PBS only control. Data are mean ± SEM, for a minimum of n = 3 independent
experiments.
Marker Gene or
Protein
Stimulus
LPS IL-1b TNFa IL-4 IL-10 IFNc
CD16 G 0.43 ± 0.01 0.40 ± 0.01 0.36 ± 0.04 1.43 ± 0.06 0.62 ± 0.03 0.58 ± 0.03 M1, Cytotoxic
CD32 G 1.63 ± 0.26 1.04 ± 0.09 1.10 ± 0.22 2.04 ± 0.34 0.97 ± 0.23 0.03 ± 0.01
CD86 G 2.33 ± 0.21 1.09 ± 0.12 1.03 ± 0.14 0.62 ± 0.10 0.15 ± 0.03 1.15 ± 0.17
Cox-2 G 1248.00 ± 257.40 34.63 ± 4.06 45.70 ± 4.08 1.63 ± 0.28 0.25 ± 0.07 20.32 ± 9.82
iNOS G 2529.00 ± 279.80 215.10 ± 15.17 215.40 ± 16.05 1.06 ± 0.36 1.68 ± 0.33 85.38 ± 11.52
IL-1b P 283.60 ± 46.61 NA 206.20 ± 29.51 0.18 ± 0.07 2.77 ± 0.26 0.14 ± 0.03
IL-6 P 18632 ± 4127.00 2396.00 ± 518.10 2999.00 ± 717.40 1.04 ± 0.48 20.01 ± 8.61 1.17 ± 0.15
IL-12 (p70) P 60.31 ± 0.86 15.89 ± 1.64 16.53 ± 0.77 9.22 ± 0.66 4.99 ± 0.91 0.48 ± 0.21
TNFa P 16085 ± 1931.00 315.90 ± 85.20 NA 1.02 ± 0.08 1.46 ± 0.51 1.07 ± 0.27
CXCL1 (KC) P 1518.00 ± 249.40 764.30 ± 128.90 1104.00 ± 158.00 0.96 ± 0.40 14.80 ± 1.38 0.73 ± 0.14
CD206 G 0.01 ± 0.002 0.04 ± 0.003 0.04 ± 0.003 3.99 ± 0.45 0.47 ± 0.05 0.03 ± 0.001 M2a, alternative repair
and regenerationArg1 G 0.48 ± 0.24 0.63 ± 0.30 0.50 ± 0.28 2763.00 ± 509.90 1.30 ± 0.33 0.22 ± 0.07
IGF-1 G 0.08 ± 0.001 0.18 ± 0.02 0.18 ± 0.02 1.52 ± 0.08 0.12 ± 0.002 0.06 ± 0.001
Gal-3 G 0.33 ± 0.02 0.36 ± 0.03 0.34 ± 0.02 2.03 ± 0.11 0.14 ± 0.01 0.72 ± 0.02
CCR2 G 0.22 ± 0.02 0.17 ± 0.02 0.14 ± 0.003 1.13 ± 0.13 0.27 ± 0.05 0.70±0.07
TGFb G 0.67 ± 0.01 0.95 ± 0.09 0.84 ± 0.05 1.03 ± 0.14 0.36 ± 0.07 0.56 ± 0.04
CX3CR1 G 0.001 ± 0.0001 0.03 ± 0.01 0.02 ± 0.002 0.16 ± 0.02 0.14 ± 0.02 0.06 ± 0.01
CCL2 (MCP-1) P 2.22 ± 0.22 1.16 ± 0.21 1.35 ± 0.15 0.05 ± 0.003 0.23 ± 0.04 0.20 ± 0.01
IL-1RA G 109.80 ± 5.75 9.12 ± 0.95 8.21 ± 0.28 1.15 ± 0.17 3.12 ± 0.60 1.08 ± 0.08 M2b, immuno-
modulatorySOCS3 G 62.66 ± 5.66 10.11 ± 1.06 9.86 ± 1.09 0.66 ± 0.11 11.70 ± 2.11 3.81 ± 0.72
Sphk1 G 2.54 ± 0.13 0.36 ± 0.12 0.39 ± 0.09 1.43 ± 0.14 0.79 ± 0.03 0.43 ± 0.04
Sphk2 G 0.86 ± 0.05 0.69 ± 0.14 0.65 ± 0.07 0.59 ± 0.07 0.34 ± 0.06 0.53 ± 0.06
IL-4Ra G 1.15 ± 0.13 1.87 ± 0.20 1.49 ± 0.26 0.40 ± 0.05 4.97 ± 0.48 1.10 ± 0.13
IL-10 P 61.52 ± 4.75 26.64 ± 2.23 23.59 ± 1.13 13.38 ± 0.41 NA 0.35 ± 0.10
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M2a-repair/regeneration markers. The magnitude of these in-
creases in M1 and M2b markers was greatest in LPS stimulated
microglia (Table 2).
IL-10 was the only stimuli to induce gene expression for IL-4Ra
at 12 h (Table 2), and of note expression was still greater than
3-fold above control at 36 h (data not shown). The response to
IL-10 was also unique in that it was the only stimuli to increase
gene expression for markers ascribed to M2b immunomodulatory
markers at 12 h, but did not increase either cytotoxic M1 or repair
M2a markers (Fig. 2E). However, IL-10 induced a similar proﬁle of
cytokine/chemokines to that of LPS, TNFa, and IL-1b, (increased
IL-6, CXCL1, and CCL2) although the levels were considerably
lower. (Table 2; Supplementary Table 2).
The known anti-inﬂammatory cytokine IL-4 was the only stim-
ulus that increased gene expression of M2a-repair/regeneration
phenotype markers; arginase-1 (Arg1) and CD206. Also, IL-4 was
the only stimulus that did not increase gene expression for M2b-
immunomodulatory phenotype markers (Table 2; Supplementary
Table 2). IL-4 did not increase release of any cytotoxic M1 markers,
such as IL-1b, IL-6, TNFa or CXCL1 (Table 2; Supplementary
Table 2).
Collectively from this data we concluded that each of the pro-
inﬂammatory stimuli (LPS, IL-1b, TNFa or IFNc) induced markers
of both cytotoxic M1 and immunomodulatory M2b activation
state. However, the magnitude of marker increase was highest
for LPS and this was chosen as our pro-inﬂammatory stimulus
for later experiments. IL-4 was designated our anti-inﬂammatory
inducing stimulus due to its speciﬁc actions to increase markers
known to indicate functions of repair and regeneration.
3.2. Gene expression levels discriminate between microglial
phenotypes
Using our selected M1/2b and M2a inducing stimuli (+LPS and
+IL-4, respectively) we investigated the temporal proﬁle ofexpression of phenotype markers (at 4, 12, 36, and 72 h), via gene
expression (Fig. 2). We sought to determine how many of the clas-
sical and more novel markers would have predictive value in this
in vitro system for characterising phenotype.
We identiﬁed several key strong discriminatory markers for
phenotype over time. In response to the prototypical microglial
activator LPS, gene expression of the M1 markers iNOS, CD86 and
Cox-2 were increased at 4 h, and iNOS and Cox-2 remained ele-
vated at each subsequent time point assessed. Similarly, the M2b
markers IL-1RA and SOCS3 were also elevated at 4 h and remained
elevated following exposure to LPS. To ensure that the apparent co-
incident induction of M1 and M2b was not due to the ﬁrst sample
being at 4 h after stimulation, samples were taken from 15, 30, 60,
120, and 240 min after stimulation. This revealed that markers of
both phenotypes were induced in parallel, and within 120 min
(Supplementary Fig. 1). Overall, in response to the M1/2b inducer
LPS, gene expression for M2a markers were strongly reduced over
time (Fig. 2).
In M2a inducing conditions (+IL-4), expression of CD206 and
IGF-1 was greatest at 4 h and declined over time. However, Arg1
and CCR2 increased with time and were highest at 36 and at
72 h, respectively (Fig. 2). Also, expression was greatly induced at
72 h for the M2a markers FIZZ1 and YM1, but we were unable to
ﬁnd either expressed in basal conditions or after IL-4, with which
to normalise expression and they are shown in Supplementary
Data (Supplementary Fig. 2). Overall, in response to the M2a indu-
cer IL-4, gene expression for M1/2b markers was stable or reduced.
3.3. Classic pro-inﬂammatory cytokines discriminate between
microglial phenotypes
Expression over time of a number of cytokines/chemokines
from stimulated microglia (Fig. 3) had a proﬁle speciﬁc to an M1
or M2 phenotype. Exposure to the M1/2b inducer LPS increased
expression of all cytokines and chemokines in all phenotype cate-
gories, at 12, 36, and 72 h (Fig. 3). IL-4 also increased expression of
Fig. 2. Gene expression of phenotype markers over time in response to M1 or M2 inducing conditions. Expression of phenotype markers grouped as M1 (White), M2a (grey)
or M2b (black) dependent on their proposed function, in primary microglia exposed to M1/2b inducing conditions (+LPS) or M2a inducing conditions (+IL-4), for 4 h, 12 h,
36 h or 72 h. Expression shown relative to PBS only, dotted line. Data are mean ± SEM of at least 3 experiments. Data were assessed via an ANOVA, and where signiﬁcant the
results of the Bonferroni post-test are shown; ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001, compared to PBS.
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Fig. 3. Protein expression for phenotype markers over time in response to M1 or M2 inducing conditions. Expression of phenotype markers in the conditioned media, grouped
as M1 (White), M2a (grey) or M2b (black) dependent on their proposed function, from primary microglia exposed to M1/2b inducing conditions (+LPS) or M2b inducing
conditions (+IL-4), for 4 h, 12 h, 36 h or 72 h. Expression shown relative to PBS only, dotted line. Data are mean ± SEM of at least 3 experiments. Data were assessed via an
ANOVA, and where signiﬁcant the results of a Bonferroni post-test are shown; ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001, compared to PBS.
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Fig. 4. Expression of selected phenotype markers in cultured microglia. Microglia were stained with markers as indicated after exposure for 12 or 36 h to LPS or IL-4, with PBS
as control. All photomicrograph were taken at 63magniﬁcation, scale bar 25 lm. Panels A–F, Cox-2 in red, IL-1RA in green and Hoechst in blue. Panels G–L, Arg1 in red, iNOS
in green and DAPI in blue.
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tiple time points. However, in response to IL-4, the M1 associated
factors IL-6, TNFa, and CCL5 were not increased at any assessed
time point. As these markers were increased at all time points by
LPS they are useful discriminatory markers. The M1 and M2b
markers G-CSF, GM-CSF, IL-1b, and IL-1a were also not increased
by IL-4, and induced by LPS at 12, 36, and 72 h, proving useful to
discriminate between phenotypes at later than 4 h of stimulation.
In summary of the timing of marker expression (measured as
either gene or protein expression; Figs. 2 and 3); the majority of
M1 markers (10/13) and M2b markers (8/13) were maximally ex-
pressed at 12 h of exposure to LPS. In response to IL-4, seven of the
twelve M2a markers were increased at 36 h and there was a max-
imal reduction of the M1/2b markers, CD16, CD32, CD86, IL-4Ra,
SOCS3, SphK2. As such, during additional experiments microglia
were exposed to 12 h of LPS to induce maximal M1/2b and IL-4
for 36 h for maximal M2a phenotype.3.4. Immunohistochemistry correlated with gene expression of the
selected markers
To identify the distribution of phenotype markers within cells
and between cells exposed to LPS or IL-4, microglia were double la-
belled. Microglia were labelled with an M1 and an M2a or M2b
marker i.e., iNOS and Arg1 (Fig. 4A–F), Cox-2 and IL-1RA
(Fig. 4G–L) or CD86 and Arg1 (Supplementary Fig. 3).Cox-2 and IL-1RA expression increased following exposure to
LPS, but of interest, it appeared that cells preferentially increased
only one of these markers. In some cases microglia appeared to
have low levels of IL-1RA and Cox-2 (Fig. 4E). Activation with
IL-4 caused IL-1RA to be diffusely distributed within the cyto-
plasm, whereas in PBS and LPS (at 12 h) treated microglia it
appeared as distinct granules near the nucleus. Exposure to IL-4
caused an almost complete loss of IL-1RA and Cox-2 expression
at 36 h (Fig. 4D vs. 4F). Nevertheless, at 12 h, compared to PBS it
appears there was an induction of Cox-2.
Activation of microglia with IL-4 induced Arg1 and this up-reg-
ulation was greatest at 36 h. Activation with LPS or IL-4 caused
Arg1 staining to appear as distinct ﬁbres wrapping around the nu-
cleus and extending into the processes, reminiscent of microtubule
staining (Fig. 4K and L). For Arg1 expression was reduced in LPS
treated cells at 36 h, but surprisingly a very occasional microglia
displaying strong staining Arg1 was seen.
Following 12 h of exposure to LPS, expression of iNOS was obvi-
ously increased, with the appearance of punctate cytoplasmic
granules. At 36 h of LPS, the cells were very intensely stained for
iNOS with even larger granules within the cytoplasm surrounding
the nucleus, but not into the processes. In contrast, exposure to
IL-4 caused an almost complete loss of iNOS at both time points.
CD86 expression, as expected from gene data, did not appear to
change substantially over time (Supplementary Fig. 3).
In addition, we investigated whether LPS or IL-4 altered expres-
sion of Ki67, a marker of proliferation. We observed a signiﬁcant
Fig. 5. Phenotype of microglia alters the neuronotoxicity of conditioned media. Total appearance of cell death markers (A, C) and relative numbers of speciﬁc cell death type
markers (B, D) in neurons exposed for 14 h to conditioned media harvested following 12 h (A, B, F–H) or 36 h (C, D) induction to an M1/2b or M2a phenotype, or PBS. Viability
was assessed dependent on positive staining for 7-ADD, Annexin V, or both (see example, E), and speciﬁcally neurons were categorised as ‘normal’ (blue arrow) double
negative and Hoechst positive, Annexin V positive only (red arrow), 7AAD+ positive only (green arrow), Annexin V+ and 7AAD+ with uncondensed nuclei (white arrow) or
Annexin V+ and 7AAD+ condensed nuclei (orange arrow). Cells double positive with an uncondensed nuclei (white arrow) were very extremely rare. Representative images
taken after exposure of neurons to 12 h CM for 14 h (F–H), illustrating basal staining of neurons in F (+PBS CM), increased cell death in +LPS CM (G), and deceased cell death in
+IL-4 CM (H). Scale bar 25 lm. Data are mean ± SEM of at least 3 experiments. Data were assessed via an Kruskal Wallis, and where signiﬁcant results of a Dunn’s post-test are
shown; ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001, compared to PBS.
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induction of M1/2b (LPS, 12 h), and a signiﬁcant 75% reduction
where microglia were maximally M2a (IL-4, 36 h) (Supplementary
Fig. 4).3.5. Neuronal viability is increased by soluble factors from M2a
microglia and decreased by soluble factors from M1/2b microglia
Neurons were exposed to soluble factors (i.e. conditioned med-
ia), from microglia induced to an M1/2b or M2a phenotype with
LPS or IL-4, (or PBS as control), in a model of growth factor depri-
vation mediated neuronotoxicity, as previously described (Dean
et al., 2010). In brief, microglia media is deﬁcient in neuronal
growth factor supplements and neuronotoxicity was approxi-
mately 60% at 24 h in response to switching to 1/3rd of uncondi-
tioned microglial media. We assessed the effects of media
conditioned by microglia for 12 or 36 h on this neuronotoxicity
and measured the proportion of cells positive for markers of cell
death at 5, 8, and 14 h of exposure to the media; at 5 and 8 h effects
of media type on death were negligible (Supplementary Fig. 5).
Factors in the media conditioned by M2a microglia for 12 h
strongly reduced the total percentage of neurons positive for mark-
ers of cell death (Fig. 5A and B). More speciﬁcally (Fig. 5B), this
media reduced the proportion of neurons positive for 7-AAD (ne-
crotic-like) or Annexin V+/7-AAD+/condensed chromatin (late
stage apoptotic-like). Where M2a microglia conditioned the media
for 36 h, overall neuronotoxicity was reduced (Fig. 5C), but this ef-
fect was not as strong as for the media conditioned for 12 h.
In contrast, media conditioned by LPS treated microglia to be-
come M1-cytotoxic caused a greater number of neurons to be po-
sitive for cell death markers after 14 h of growth factor deprivation.This is seen as a signiﬁcant increase in the overall number of cells
positive for cell death markers (Fig. 5A) or speciﬁc changes in the
proportion of cells positive for Annexin-V+ (apoptotic-like death)
(Fig. 5D).3.6. Prior phenotype affects the subsequent expression of phenotype
markers
Inﬂammatory events inﬂuence the reactivity of glia in the brain
long-term and any prior activation state of microglia is likely to al-
ter the efﬁcacy of immunomodulatory therapies (Nagamoto-Combs
et al., 2007; Ramlackhansingh et al., 2011). In addition, microglia
have been shown to be M2 immediately following injury so it is
imperative to understand how they respond to further stimulation
(Hu et al., 2012). As such, we characterised how prior phenotype
alters development of the alternate phenotype. Microglia were in-
duced to a maximal M1/2b phenotype (+LPS for 12 h), or a maximal
M2a phenotype (+IL-4 for 36 h). The conditionswere then switched,
with LPS removed and replaced with IL-4 for 36 h or IL-4 removed
and replaced with LPS for 12 h (Figs. 1 and 6).
Acquiring an M2a phenotype (+IL-4) before switching to an M1/
2b (+LPS) caused expression of the M1 marker CD86 to be signiﬁ-
cantly greater (Fig. 6). However, previous exposure to an M2a
inducing condition (+IL-4) before LPS did not prevent the typical
induction of M1 markers (Cox-2, iNOS, CD32 and CD86) or the
typical induction of M2b markers (IL-1RN, SOCS3 and IL-4Ra).
Pre-acquisition of an M2a phenotype also prevented the typical
reduction in the expression of IGF-1 caused by LPS (Fig. 6), but
did not prevent LPS from reducing expression of the M2a markers
Arg1, CD206 and Gal-3 (Mac-2).
Fig. 6. Prior phenotype alters the expression of phenotype markers in response to a second stimuli. Microglia were exposed to a single stimulus (LPS for 12 h or IL-4 for 36 h)
or after one stimulus was removed it was replaced with the alternate stimulus as indicated. Gene expression is shown for markers grouped as M1 (white), M2a (grey) or M2b
(black) dependent on their proposed function. Expression shown relative to PBS only treated control values from the respective time points, dotted line. Data are mean ± SEM
of at least 3 independent experiments and assessed via Student’s t-test (primary stimuli vs. switched); ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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notype (+LPS) before switching to M2a inducing conditions
(+IL-4) prevented the loss of M1 marker CD32 typically seen after
IL-4 exposure. However, this did not prevent the typical reduction
in M1 markers, Cox-2, iNOS, CD86 (Fig. 6).
Interestingly, acquisition of an M2a-repair/regeneration pheno-
type prior to induction of an M1/2b phenotype had contradictory
and synergistic effect on SphK1 and IL-4Ra. SphK1 was reduced to
below that observed in single exposure conditions alone and con-
versely IL-4Ra was greater compared to either single exposureconditions. Prior M1/2b phenotype had no effect on the character-
istic decrease in the M2b markers, (SOCS3 or IL-1RA), in response
to IL-4 (Fig. 6).
IL-10 induced a speciﬁc phenotype, and thus, we also assessed if
acquisition of anM1/2b phenotypewould alter the ability of IL-10 to
induce our M2b markers (Fig. 7). Inducing an M2b only phenotype
(+IL-10) before inducing an M1/2b phenotype (+LPS) prevented
the typical response of increased iNOS, Cox-2, SphK1, and SOCS3.
Moreover, pre-exposure to IL-10 exacerbated the typical reduction
of Arg1 and Gal-3 by LPS, causing an even greater decrease (Fig. 7).
Fig. 7. Prior IL-10 exposure impairs the development of a later M1/2b phenotype. Microglia were exposed to single or consecutive treatments of LPS (12 h) or IL-10 (12 h) as
indicated and shown is gene expression for markers grouped as M1 (White), M2a (grey) or M2b (black) dependent on their proposed function. Expression shown relative to
PBS only treated control values from the respective time points, dotted line. Data are mean ± SEM of at least 3 experiments assessed via Student’s t-test (primary stimuli vs.
switched); ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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factors
We must consider the effects of microglial products on neuro-
nal survival following the combination of insult and immuno-
modulatory stimuli. As such, conditioned media was collected
from the phenotype switching experiments and the effect of this
prior phenotype on neuronal viability was assessed (Fig. 8). To do
this we used the aforementioned growth factor deprivation mod-
el of neuronotoxicity and monitored the numbers of cells posi-
tive for Annexin V and/or 7-AAD, as surrogates for cell death.Prior induction of M2a phenotype (+IL-4) signiﬁcantly reduced
the toxicity of conditioned media from microglia then stimulated
to become M1 cytotoxic with LPS (Fig. 8). Pre-induction to M1/2b
phenotype (+LPS) did not alter the neuroprotective effects of
media conditioned by subsequently IL-4 treated microglia.
Interestingly, media from both switching paradigms caused less
neurons to be positive for Annexin V, but this was greater for
the IL-4-to-LPS media. In contrast, both switches appeared to
increase the numbers of mixed Annexin V+ and 7-AAD+ cells,
but this increase was only signiﬁcant for IL-4-to-LPS conditioned
media (Fig. 8).
Fig. 8. Prior phenotype reduces the neuronotoxicity of soluble factors from cytotoxic microglia. Neurons were exposed to conditioned media from microglia induced to a
phenotype with a single stimulus (LPS 12 h or IL-4 36 h), or where the two treatments were applied in succession, with media changed between stimuli. After exposure to
conditioned media for 14 h, the number of cells positive for cell death markers 7-AAD or Annexin V was assessed relative to total cell number (Hoechst positive). Data are
mean ± SEM of at least 3 independent experiments assessed via Mann Whitney (single stimulus vs. switched); §p = 0.05; ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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This aim of this study was to create a comprehensive analysis of
microglial phenotype, including effects on neuronotoxicity, which
can be used as a reference tool to identify the immunomodulatory
potential of novel compounds. Inasmuch, for the ﬁrst time this
study outlines an in vitro model in which expression of thirty-
one classical and more novel phenotype markers has been
characterised in a time and stimulus dependent manner. All of
the measured phenotype markers have important functions in
inﬂammation. A complete review of their activities is outside the
scope of this discussion, however, identifying how, and when,
novel compounds modulate their expression is important in the
design of viable efﬁcacious neurotherapeutic paradigms. Function-
ally, we characterised how necrotic-like and apoptotic-like death is
exacerbated by soluble factors from M1/2b induced microglia and
reduced by soluble factors from M2a stimulated microglial. Wealso noted that prior phenotype had persistent and functional
implications during the acquisition of a later phenotype.
4.1. Induction and timing of microglial phenotype
Our ability to identify the activation state of microglia is critical
for timing any therapy. It was considered that an M1 cytotoxic
phenotype develops due to insult/injury and that the same cell
transitions to an M2-repair/regenerative phenotype over time
(Stout et al., 2005; Kigerl et al., 2009; Perry et al., 2010). However,
the presence of an early M2 phenotype (preceding M1) has re-
cently been reported after hypoxic/ischemic injury in vivo (Hu
et al., 2012). This study indicated that M2 markers were increased
at 1 day, and persisted for up to 7 days after injury, overlapping
with increases in M1 markers. In agreement with a prolonged evo-
lution of a M2a repair and regeneration phenotype, key M2
markers were maximal following only 4 h of stimulation and
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tective effect. However, greater than half of the M2a markers did
not peak in expression or release until far later (36–72 h). If there
are discreet temporal phases of phenotype these may be druggable
to affect neuroprotection. As such, assessment of temporal shifts in
expression patterns may be as important as arbitrary increases or
decreases in total activation when trialling therapies in vitro.
As just mentioned, soluble factors from the early phase (ﬁrst
12 h) of M2a repair and regeneration microglia were more neuro-
protective than products collected until maximal M2a gene and
cytokine expression (at 36 h). Early increases in IGF-1 and TGFb
are likely important, given their known neuroprotective capacity
(Henrich-Noack et al., 1994; Brywe et al., 2005). Also, although
identiﬁcation of novel soluble factors was outside the scope of this
study, unknown microparticles (microvesicles, microRNA, bioac-
tive lipids) (Antonucci et al., 2012), may have contributed to re-
duced neuronotoxicity and may themselves be interesting
neurotherapeutics (Turola et al., 2012). Striking changes in the pro-
portions of cells undergoing apoptotic or necrotic death were not
observed. However, the mechanisms governing apoptosis and
necrosis and as such the drugs targeting these processes are differ-
ent. As such, when screening the effects of novel therapies includ-
ing considering the utility of any pathway speciﬁc adjunct therapy,
this analysis may be of importance.
4.2. Discriminating between microglial phenotypes
All pro-inﬂammatory stimuli induced a similar (if different
magnitude) overall gene and cytokine response in microglia in
general agreement with what has previously been reported (see,
Colton, 2009; Ransohoff and Perry, 2009). Similarly, M1 markers
can also be induced with beta-amyloid and agonists of group II
metabotropic glutamate receptors and via other toll-like receptors
in microglia and macrophages (Michelucci et al., 2009; Colton and
Wilcock, 2010). This further indicates redundancy in this induction
process, which has been suggested to involve the adaptor proteins
MyD88 (Esen and Kielian, 2006; Dean et al., 2010).
Speciﬁcally, as previously reported for microglia and macro-
phage in vivo and in vitro LPS induced factors including iNOS,
IL-1a, IL-6, CXCL1, CCL5 and TNFa (see, Colton, 2009; Ransohoff
and Perry, 2009). Nitric oxide produced by iNOS is cytotoxic and
each of these M1markers is increased in brain and/or blood follow-
ing brain injury or during inﬂammation (Dammann and Leviton,
1997; Hedtjarn et al., 2004; Helmy et al., 2011). In particular, in-
creased IL-6 and TNFa is linked to a poor prognosis in infants suf-
fering encephalopathy (Savman et al., 1998; Aly et al., 2006), these
factors known to stimulate extrinsic pathways of cell death (Sidoti-
de Fraisse et al., 1998). As such, these factors are assigned as M1-
cytotoxic markers. We also observed that LPS increased expression
of colony stimulating factors (G-CSF and GM-CSF), which may ex-
plain the increase in proliferation of microglia at 12 h (Giulian and
Ingeman, 1988). Of note, the induction of an M1-cytotoxic pheno-
type also strongly decreased expression of M2a repair/regenera-
tion markers, in agreement with reports that acquisition of
phenotype requires a complex amalgam of induction and repres-
sion of gene expression (Liao et al., 2011).
Phenotypes have been considered separable stages in a tempo-
rally transitioning continuum (Mantovani et al., 2007; Kigerl et al.,
2009). However, all pro-inﬂammatory stimuli induced M1 markers
in parallel with the M2b markers SOCS3, SphK1 and IL-1RN. These
3 factors are associated with a M2b-deactivating or immunomod-
ulatory phenotype, as SOCS3 reduces aberrant IL-6 family member
activation (Croker et al., 2003); SphK1 catalyses the formation of
sphingolipids with potent cell survival and proliferative effects
(Bryan et al., 2008); and IL-1RA is an endogenous antagonist of
IL-1 receptor activity (Akuzawa et al., 2008). We demonstrated thatco-induction occurred as early as 2 h following stimulation, sug-
gesting that these genes are independently induced. However, it
is plausible that the rapid induction of Cox-2 by LPS drove in-
creased M2b marker expression. Prostaglandins induce IL-1RN,
SOCS3, SphK1/2, and IL-4Ra and as such, Cox-2 can be considered
an M2b marker (Mosser and Edwards, 2008; Colton, 2009; Ranso-
hoff and Perry, 2009).
Decreased expression of the T-cell stimulating factor IL-12 has
been considered a hallmark of an M2b phenotype (Mantovani
et al., 2009, David and Kroner, 2011). Although we did not observe
this decrease, autocrine signalling and microglia-macrophage dif-
ferences (discussed below) may explain this variation from previ-
ous reports.
Co-induction of cytotoxic and immunomodulatory markers, has
previously been reported in the brains of adult mice following
peripheral LPS (Fenn et al., 2012), and in macrophages in vitro,
termed a hybrid phenotype (Mosser and Edwards, 2008). Increas-
ing evidence indicates that diversity in marker expression is due
to separable heterogeneous microglial populations, not simply
co-expression of markers in the same cell (Lawson et al., 1990;
Elkabes et al., 1996). Together with the temporal variation in mar-
ker expression, this governs the need to replicate both a wide
selection and the time course to generate a ﬁrst-line analysis of
the effect of any therapeutic agent.
In response to IL-4, as previously reported, microglia increased
the expression of CD206, Arg1, IGF-1, Gal-3, and CCR2
(Martinez-Pomares et al., 2003; Fenn et al., 2012). Expression of
these markers is consistent with a repair/reparatory phenotype,
as CD206 is a mannose receptor which stimulates phagocytosis
(Zimmer et al., 2003); IGF-1 is a cytoprotective growth factor
(Johnston et al., 1996); Arg1s catalytic activity produces poly-
amines that support extracellular matrix repair and mitochondrial
function (Pesce et al., 2009); and Gal-3 is a modulator of prolifera-
tion (Inohara et al., 1998), and oligodendrocyte maturation and
remyelination (Pasquini et al., 2011). Within this model system, in-
creased Arg1 was the only marker able to positively discriminate
an M2a phenotype at all time points. Bioavailability of the common
precursor (arginine) of Arg1 and iNOS within the subcellular
microdomains is thought to play an important role in phenotype,
not the presence of the enzymes themselves (Hesse et al., 2001).
However, we observed that microglia tended to predominantly
increase expression of either enzyme suggesting, at least in this in-
stance, it is enzyme levels that may play a role. The ﬁbrous staining
pattern we observed for Arg1 has been previously seen in LPS stim-
ulated microglia (Scheffel et al., 2012), and may reﬂect increased
transport via microtubules, reported previously in endothelial cells
for arginase-2 (Ryoo et al., 2006). Exposure to IL-4 reduced the pro-
liferation of microglia, unexpected as IL-4 has been previously
shown to have no effect or to increase microglial proliferation
in vitro (Suzumura et al., 1991, 1994).
4.3. A microglial molecular memory
Any immunomodulatory neurotherapy is going to interact with
microglia already activated by insult or injury. It is therefore criti-
cal we understand how microglia respond when pre-conditioned.
Furthermore, there is increasing clinical evidence of persisting
microglial activation following brain injury, increasing susceptibil-
ity to neurodegenerative diseases. As such, we need to understand
this molecular memory and any ability to switch the states of acti-
vated microglia (Long-Smith et al., 2009; Pinkston et al., 2009).
Prior activation state synergistically and in a gene speciﬁc manner
altered later development of an opposing phenotype. A similar
complex synergy between phenotypes has been previously re-
ported in microglia (Stout et al., 2005; Fenn et al., 2012). Of
particular physiological relevance, prior exposure to IL-4 has been
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et al., 2009). Similarly, we observed that prior exposure to IL-4 al-
tered the later response to LPS, and importantly, reduced the re-
lease of soluble neuronotoxic products from microglia. In
macrophages, regions regulating transcriptional activity (enhanc-
ers) are modiﬁed by primary stimulus (such as LPS) leading to
genes becoming promiscuous to secondary stimulus (such as
IL-4) (Ghisletti et al., 2010). This phenomenon of cryptic enhancer
region modiﬁcation may underpin the molecular memory in this
model. Further, we know that the activation of speciﬁc transcrip-
tion factors is critical for the acquisition of phenotype (Stat1/6,
PPARc or Kruppel like factor) (Vats et al., 2006; Odegaard et al.,
2007; Liao et al., 2011). However, little is known about the interac-
tions between these factors and possible cross-regulatory signal-
ling that might explain the modulation by switching, such as
microRNAs (Jennewein et al., 2010).4.4. Interleukin-10 an immunomodulatory stimulus
Exposure to IL-10 (or TGFb or glucocorticoids) induces a speciﬁc
phenotype in macrophages, termed M2c. This phenotype is charac-
terised by high levels of anti-inﬂammatory cytokines, low levels of
pro-inﬂammatory cytokines and increased IL-4Ra, Arg1, SOCS3
and CD206 (O’Farrell et al., 1998; Mantovani et al., 2004; David
and Kroner, 2011). It is thus unsurprising that administration of
IL-10 reduces experimental brain injury in vivo and in vitro (Spera
et al., 1998; Molina-Holgado et al., 2001; Mesples et al., 2003).
Interestingly, in our model IL-10 was the only stimuli to increase
expression of IL-4Ra, in agreement with previous reports, but in
contrast there was no loss of M2a-repair/regenerative marker
expression (CD206 and Arg1) (O’Farrell et al., 1998; Imai et al.,
2007). Also as expected, IL-10 prior to LPS inhibited M1-cytotoxic
marker expression (O’Farrell et al., 1998; Kremlev and Palmer,
2005). Conversely, when the treatments were reversed (i.e. LPS be-
fore IL-10) expression of M2b-immunosuppresive markers was
lower, indicating that microglia can lose the ability to respond to
this anti-inﬂammatory stimulus.4.5. Unique microglial activation
The origins and responsiveness to stimuli of microglia and
blood-derived macrophages reportedly differs (Schmid et al.,
2009; Dibaj et al., 2011; Saijo and Glass, 2011; Kierdorf et al,
2013). Differences in timing and dosages between studies limit
any conclusive statements regarding microglia vs. macrophage re-
sponses from this data. However, in our study, compared to macro-
phages in response to IL-10 the Fcc receptor CD16 was not
increased (Wang et al., 2001), and IL-4 and LPS both reduced
CX3CR1 (fractalkine receptor) expression (Ramos et al., 2010).
These differences warrant further investigation to ensure that no-
vel neurotherapeutics are optimised to modulate both the resident
and inﬁltrating populations of immune cells participating in injury
and repair processes.
In conclusion, we have presented a comprehensive set of data
on phenotype markers and function that is unique in its inclusion
of such a great number of classic and novel markers, and analysis
over time. We also present additional support for the hypothesis
of a functionally relevant microglial molecular memory that will
be crucial in considering the in vivo response of microglia. Alto-
gether, by using this data as a reference it will be possible to iden-
tify, as part of a ﬁrst line screening process, the capacity for
reducing cytotoxicity and/or supporting regeneration and repair
of novel immunomodulatory compounds.Conﬂict of interest
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